Chemotherapy-associated thrombosis.
Ashrani
Aneel A
AA
Division of Hematology, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA. ashrani.aneel@mayo.edu
Rajkumar
S Vincent
SV
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008954:Models, Biological; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy; D009196:Myeloproliferative Disorders / Q000097:blood / Q000150:complications; D009369:Neoplasms / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D011994:Recombinant Proteins; D012306:Risk; D019851:Thrombophilia / Q000139:chemically induced; D013927:Thrombosis / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control; D054556:Venous Thromboembolism / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control
D000305:Adrenal Cortex Hormones; D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D011994:Recombinant Proteins; D004921:Erythropoietin